OBJECTIVES: Downsizing a homograft (HG) through bicuspidalization has been used for more than 2 decades to overcome the shortage of small-sized conduits for reconstruction of the right ventricular outflow tract (RVOT) in young children. Our goal was to investigate the durability of bicuspidalized HGs compared with other small HGs.
INTRODUCTION
Valved conduits are frequently used for reconstruction of the right ventricular outflow tract (RVOT) in patients with congenital cardiac anomalies with absent or failing pulmonary valves. The use of fresh, and later cryopreserved pulmonary or aortic homografts (HGs), has facilitated this reconstruction due to the wide applicability of the material compared to previously used bioprosthetic conduits [1, 2] . However, the limited availability of small HGs for neonates and young children has triggered the search for alternatives. Small xenograft conduits have gained popularity over the last decades [3] because of their off-the-shelf availability, but their superiority compared with small HGs at mid-term follow-up remains questionable [4] [5] [6] . In the mid-1990s, a surgical technique for downsizing a large HG into a bicuspid conduit was reported [7] [8] [9] . Since then, a handful of papers on small groups of patients treated with this technique have been published, most of which demonstrate equal outcomes compared with the standard HGs in the short term [10] [11] [12] [13] [14] [15] . We have used this technique since 1995 as an alternative for a xenograft conduit when a small standard HG was unavailable. Because every conduit type used in young children will eventually require replacement due to degeneration or outgrowth, the analysis focused on the patients who received a right ventricle-to-pulmonary artery conduit of < _ 20 mm diameter to study the durability of the bicuspidalized HGs compared with the standard HGs or xenografts implanted during the same period.
MATERIALS AND METHODS

Patients and conduits
From 1993 to 2015, 298 consecutive RVOT conduits were implanted in 232 patients in the Cardiac Centre of the University Hospital Ghent, Belgium. Of these, 106 RVOT conduits were sized < _20 mm. A standard pulmonary HG was preferentially chosen as the first option for RVOT reconstruction. When no appropriately sized pulmonary HG was available, an alternative RVOT conduit was chosen at the discretion of the surgeon. Considering the policy of slightly oversizing the RVOT repair, our goal was a target conduit z-value of > _2.
Standard pulmonary and aortic HGs have been used since 1993; bicuspidalized HGs have been utilized since 1995 and xenograft conduits were introduced in 1999. Cryopreserved HGs were obtained from the European Homograft Bank (Brussels, Belgium). Xenografts consisted of bovine jugular vein glutaraldehyde-treated grafts (Contegra V R , Medtronic Inc.). Other xenograft valves were used occasionally during the same period but were excluded from the study because only a few were implanted (9 Labcor V R stentless conduits and 4 stented bioprostheses). Bicuspidalization was performed on pulmonary HGs only, according to the previously described technique, thus reducing the original diameter of the pulmonary conduit by one-third [7, 9] . The graft was prepared in the operating theatre, before the start of extracorporeal circulation. In total, 93 RVOT conduits < _20 mm comprised the analysis.
Right ventricular-to-pulmonary artery conduits were implanted in the orthotopic position on the original pulmonary valve site if applicable or in a heterotopic or extra-anatomic configuration, depending on the cardiac disease. All patients were routinely prescribed aspirin 5 mg/kg.
Conduit diameters were calibrated with Hegar dilators and expressed in millimetres. The z-values of the valves at implantation and at the time of replacement were converted from standard algorithms [16] . Body surface area was calculated according to the Mosteller formula for children.
Patient characteristics, surgical and interventional data, mortality and morbidity rates, echocardiographic data on conduit and cardiac function and valve explant data were prospectively and retrospectively collected from hospital files and outpatient clinics. The institutional ethical committee approved the study and waived the need for informed consent.
All surviving patients were seen routinely at least yearly at the university hospital outpatient clinic or by the referring cardiologist. Conduit follow-up ended at the time of death or conduit replacement; for patients who still had their valve implanted, the followup period ended at a common closing date (December 2016).
Definitions and study end-points
Study end-points were survival, conduit replacement and structural valve degeneration (SVD).
In-hospital death was defined as death within 30 days after the operation or during the initial hospitalization.
Conduit gradients were measured with echocardiography by peak pressure across the conduit and expressed in mmHg. Conduit regurgitation was graded from 1 to 4, in accordance with the standard echocardiographic classifications.
SVD was defined as a peak gradient of > _40 mmHg or a peak velocity of >3 m/s, pulmonary incompetence >2/4 or valve explant for any reason [17] . Conduit replacement was defined as surgical RVOT conduit exchange or transcatheter pulmonary valvulation technique.
Statistical analysis
Data were analysed with the SPSS 24.0 software (IBM Corp. Released 2016, IBM SPSS Statistics for Windows, version 24.0; IBM Corp., Armonk, NY, USA).
Distribution of the data was based on the Shapiro-Wilks test. Categorical variables are stated as number and frequency. Categorical variables were compared using the v 2 or the Fisher's exact test for smaller data sets. Continuous data are expressed as mean ± standard deviation or median and interquartile range, according to the data distribution. Continuous data between groups were compared using 1-way analysis of variance or the KruskalWallis testing, for normally and not-normally distributed data. Post hoc analysis of between-group differences was adjusted for multiplicity of pairwise comparisons using the Bonferroni correction.
Survival or freedom from event analysis was based on the Kaplan-Meier product limit estimation method. Freedom from SVD and conduit explant were expressed by percentage and 95% confidence limits, respectively. Univariable log-rank analysis was used for categorical risk factors and Cox regression for continuous risk factors. Risk factors considered to have clinical relevance were entered into a multivariable Cox regression model. The proportionality assumption of the model was verified graphically by the log-minus-log plot for the main variable of interest, by the 'type of RVOT' conduit and by plotting the Schoenfeld residuals against the ranked time for the other variables. The effect of the risk factors was expressed by the hazard ratio and 95% confidence interval (CI). A P-value of <0.05 was considered statistically significant.
RESULTS
In total, 93 RVOT conduits sized < _20 mm were implanted in 88 patients. In 22% of patients (19 of 88), a genetic abnormality was observed, mainly 22q11 deletion (11 patients). Five patients received a second conduit of < _20 mm. Patient and procedural details are listed in Table 1 . A standard pulmonary HG was implanted in 40 patients (Group P) and a bicuspidalized conduit in 17 patients (Group BC). Twelve children received an aortic HG (Group A) and 24 received a Contegra xenograft (Group X). Median patient age and weight at implantation were 1.4 years (interquartile range 0.3-3.0 years) and 8.8 kg (interquartile range 5.0-12.9 kg), respectively. In every group, more conduits were positioned extra-anatomically, depending on the original diagnosis. The orthotopic position was typical in patients with tetralogy of Fallot, the Ross procedure or absent pulmonary valve syndrome. The conduit was positioned in the heterotopic configuration in patients with truncus arteriosus, pulmonary atresia/ ventricular septal defect and the Rastelli operation for complex transposition. Diagnoses were equally distributed among the groups. In 37 patients, this was the first operation; 43 patients had previously undergone 1 operation; 9 patients had had 2 previous procedures and 4 patients underwent 3 previous surgeries. The mean conduit diameter and the z-value at implantation were 16.5 ± 2.7 mm (range 10-20 mm) and 2.8 ± 1.3, respectively. Patients from Group P were slightly older and weighed more than those in Groups BC and X. Because the conduit diameter was comparable between groups, patients in Group P had a smaller z-value at implant. Group A had the highest number of heterotopic implants.
The follow-up period ranged from 1 to 23 years and was 98% complete. The BC and X valves were introduced a few years later than the standard HGs, resulting in a slightly shorter follow-up period. Outcomes at the time of valve explant or the last followup visit are summarized in Table 2 .
Mortality and morbidity
The in-hospital mortality rate was 11% (10 patients). There were no late deaths in patients surviving the initial hospitalization or at the time of a reoperation for conduit exchange. The reasons for death were mainly cardiac in 8 patients (low cardiac output syndrome, fibroelastosis and cardiac arrest); 1 patient with pulmonary atresia/ventricular septal defect and major aortopulmonary collateral arteries had a pulmonary bleed and 1 patient died of the consequences of a neurological event. None of the deaths were valve related, and no technical issues occurred with any of the conduits.
Endocarditis was diagnosed in 3 of 23 (13%) surviving patients with a xenograft and in none of the patients with an HG. In 2 patients with a Contegra graft, acute endocarditis occurred early postoperatively: 1 patient was treated successfully with antibiotics for 6 weeks. The other patient required a conduit exchange because of a perforation. Another patient who had a Contegra conduit that showed endocarditis 2 months postoperatively was successfully treated with antibiotics.
Structural valve degeneration
A total of 83 patients were available for follow-up (37, 11, 12 and 23 conduits in Groups P, BC, A and X, respectively). Freedom from SVD for the total cohort was 79 ± 5%, 47 ± 6% and 22 ± 5% at 5, 10 and 15 years, respectively. Figure 1 illustrates the freedom from SVD for each conduit type and shows that SVD within 5 years of implantation rarely occurs in pulmonary HG conduits, regardless of bicuspidalization or aortic HG, in contrast to xenografts. Freedom from SVD at 10 years was significantly in favour of the standard pulmonary HG (68 ± 8%) compared with xenografts (20 ± 9%) (log rank P < 0.001) (Fig. 1) . Using multivariable Cox regression analysis, smaller conduit size [hazard ratio (HR) 0.79 per millimetre increase in conduit size, 95% CI 0.67-0.94; P < 0.008], extra-anatomic position (HR 2.71, 95% CI 1.33-5.50; P = 0.006) and the use of xenografts compared with nondownsized pulmonary HGs (HR 4.9, 95% CI 2.23-10.76; P < 0.001) were associated with an increased risk for SVD. Neither gender, age, the presence of a genetic syndrome nor the initial conduit z-value had a significant impact on SVD (Table 3) .
Conduit change
The decision to replace a conduit was made on a clinical basis, supported by increasing RVOT gradients, right ventricular hypertension or severe pulmonary valve incompetence with right ventricular dilatation. In total, 48 of the 83 conduits in follow-up have been replaced either surgically by another valved conduit (43 patients) or by introducing a transcatheter pulmonary stentless valve (Melody V R , Medtronic Inc.) in 5 patients. A Melody valve was implanted into 2 patients in the BC group without complications, using the prestenting technique. Freedom from conduit exchange for the total cohort was 83 ± 5%, 52 ± 6% and 26 ± 5% at 5, 10 and 15 years, respectively. The median time to conduit exchange was the shortest for xenograft conduits (Table 2 ). Figure 2 shows that freedom from conduit explants at 5 years was the lowest for Group X; however, at 10 years, half of the BC conduits and more than half of the aortic HG and xenografts had already been replaced. More than a quarter of the Group P patients still had their original conduit after 20 years (Fig. 2) .
Multivariable analysis of risk factors for conduit explants indicated smaller conduit size (HR 0.69, 95% CI 0.55-0.85; P < 0.001) and the use of xenografts compared with the standard pulmonary HG (HR 3.32, 95% CI 1.48-7.42; P = 0.004). There was no difference between the use of xenografts and aortic HG (P = 0.22) or BC HGs (P = 0.35). The anatomical position of the conduit was not retained as a risk factor (P = 0.08).
The z-values of the conduits at the time of implantation were comparable for Groups BC, A and X but larger than the z-values of Group P, as indicated in Table 1 . At the time of conduit exchange, however, the lower mean z-value in the pulmonary (-2.1 ± 1.2), bicuspid (-1.7 ± 1.2) and aortic groups (-1.5 ± 1.4) compared with the xenograft group (-0.8 ± 2.5) (P = 0.09) suggested that conduit outgrowth was the most frequent reason for explantation of HGs (Table 2) . Xenografts often failed early through a combination of other mechanisms, such as internal peel formation, severe valve incompetence or endocarditis.
DISCUSSION
In the quest for the optimal right ventricular outflow conduit in young children, the standard pulmonary HGs have long been considered the gold standard. However, the scarcity of smallsized valve allografts has motivated surgeons to search for alternative conduits in small children and neonates [4, 10] . We demonstrated that bicuspidalized HGs may offer a valid alternative, with a mid-term durability of 7-8 years that competes with adequately sized pulmonary HGs. Hence, at 10 years of follow-up, the standard pulmonary HGs are definitely superior, with a significantly higher freedom from SVD and conduit explant, confirming them as our conduit of choice. Drawing conclusions about differences in longevity beyond 10 years of follow-up may be incorrect due to the lower number of patients at risk in the other valve groups. We introduced the technique of downsizing an HG by bicuspidalization when the technique was first described [7] . The advantages are that the preparation time is short; the handling characteristics are identical to those of a standard pulmonary allograft and the tissue is more pliable than an aortic HG and easier to accommodate with the thin-walled neonatal pulmonary arteries. With the advent of xenografts, such as Contegra and Labcor, we started using these stentless conduits when no adequately sized pulmonary allograft was available. We were quickly disappointed with the Labcor conduit: it failed early with conduit obstruction due to internal peel formation, as described by others [18] . The Contegra conduit seemed promising, and we used it on several occasions with good immediate results [10] . However, Contegra conduits in neonates tend to accumulate distal scars at the pulmonary bifurcation, leading to valve degeneration [19] . When the Contegra is used in patients with pulmonary hypertension, as in truncus arteriosus, the incidence of acute conduit dilatation increases, leading to valve incompetence [20, 21] . The Contegra is also prone to endocarditis [22] , which occurred in 12% of the xenografts in our series. The less favourable 5-year freedom from SVD and valve explant and the smaller z-value at explant in the xenograft group reflect the combination of these early failure modes, which we did not encounter in the HG groups. Because every type of conduit implanted in children ultimately requires replacement mainly due to outgrowth, we always aimed for a conduit with a z-score of around 2. Several studies have demonstrated that oversized (z-value >3) or undersized (z-value <1) conduits have a greater tendency to fail early [23, 24] . The bicuspid group had larger z-values at implantation than the pulmonary group; however, this difference did not seem to influence the longevity of the conduit, because the mean z-value at conduit explant in the bicuspid group was -1.7 and not statistically different from that of the pulmonary group. In contrast, xenografts were replaced at higher z-values, indicating failure mechanisms other than pure outgrowth, as discussed previously. Conduit exchange for bicuspidalized valves was performed mainly for conduit calcification and stenosis, valve regurgitation being rare. This finding may be related to the high coaptation of the 2 remaining adult-sized valve cusps [22] .
Our study confirms the superiority of pulmonary HGs as RVOT conduits in small children. Bicuspid and aortic HGs seem to compete during the first 7-8 years after implantation and exceed the durability of xenografts at mid-term. Within the available followup time, xenografts had a 4-fold risk of developing SVD and conduit failure compared with a standard pulmonary HG, as was demonstrated by other groups [6, 25] . Only a few reports suggested a better early performance of bovine jugular vein grafts compared with pulmonary HGs in small children [26] .
Since the introduction of the bicuspidalization technique in 1994 [7] [8] [9] , only a few reports were published on bicuspidalized valves, mainly demonstrating short-and mid-term durability comparable to that of pulmonary HGs [11, 12, 14] . McMullan et al. [13] showed slightly better 5-year longevity of bicuspidalized valves compared with the standard HGs in young patients with truncus arteriosus. Yang et al. [5] used the same definitions for SVD that we did, resulting in a lower 52% freedom from valve dysfunction at 5 years for size-reduced HGs. Bramer et al. [15] provided a longer follow-up period with a median of 95 months. They demonstrated comparable SVD over time and equal freedom from reintervention with bicuspid and standard HGs in patients younger than 1 year who had the Ross procedure [15] . The largest series of 82 downsized HGs was published recently; patient age, weight and follow-up duration were comparable to the results of our study [27] . Freedom from valve failure at 5 and 10 years was 87% and 68%, respectively, for standard HGs and 78% and 61% for bicuspid HGs, slightly better than our outcomes. The bicuspid group, however, comprised significantly fewer patients with truncus arteriosus, and the z-scores at implantation were around 1.5, which may have accounted for the difference in outcomes. The risk factors for HG failure in this study were a conduit z-score <1 and age <1 year [27] .
Apart from the type of conduit, we observed the same risk factors for SVD as those observed in other series. Smaller conduit size and heterotopic implantation of the conduit are well-known risk factors for early conduit failure [28] . The fact that the majority of aortic HGs were implanted heterotopically may well have played a role in the large percentage of aortic HGs needing replacement during the study period. We found that the chance for SVD increased 21% for each millimetre decrease in conduit diameter. Age did not emerge as a risk factor for SVD in our cohort, in contrast to the results in other studies [27, 29] , probably because age is a risk factor mainly in series comparing all age groups.
Our overall valve outcomes compare favourably to those of other reports on RVOT conduit longevity, which may be partially due to different patient characteristics [24, 30] . We have always used aspirin in conduit patients, as was also suggested by others [19, 26] .
Limitations
Despite the limitations due to the retrospective design, we could trace nearly complete patient, procedural and outcome data. During the span of the study, biases might have been introduced by changes in surgical or perioperative policies; however, all operative procedures were performed by the same 2 surgeons (K.F. and T.B.), leading to a consistent approach over the years. Both bicuspidalized and xenograft conduits were introduced somewhat later in the study period, leading to shorter follow-up duration. Therefore, a smaller number of patients were at risk at 10 years compared with standard pulmonary HG.
Patients in Group P were older and weighed more than those in Groups X and BC, respectively, whereas these parameters were equivalent for Groups A, BC and X. Also, the z-values of the pulmonary HGs were smaller than in the other groups. This finding may have introduced bias in favour of Group P, but because the hypothesis was to demonstrate non-inferiority of Group BC versus Group A or X, we decided to use all patients for comparison and not to perform a propensity analysis.
CONCLUSION
We demonstrated that a cryopreserved pulmonary HG remains the most durable option for a right ventricle-to-pulmonary artery conduit in neonates and young children who are inevitably at risk for valve failure. When a small-sized standard pulmonary HG is unavailable, bicuspidalization appears preferable to the use of xenograft conduits. It offers freedom from SVD and conduit explant that is non-inferior to the standard pulmonary or aortic HG at mid-term follow-up, whereas xenografts are prone to early replacement for reasons other than pure tissue degeneration. In comparison with the currently available small xenograft conduits, bicuspidalized conduits have the additional advantage of excellent handling characteristics, minimal valve regurgitation under high pulmonary pressure and resistance to endocarditis.
